1. Bieck PR, Antonin KH (1989) Tyramine potentiation during treatment with MAO inhibitors: brofaromine and moclobemide vs irreversible inhibitors. J Neural Transm Suppl 28:21–31
2. Cassidy S, Henry J (1987) Fatal toxicity of antidepressant drugs in overdose. Br Med J 295:1021–1024
3. Da Prada M et al. (1989) Preclinical profiles of the novel reversible MAO-A inhibitors, moclobemide and brofaromine, in comparison with irreversible MAO inhibitors. J Neural Transm Suppl 28:5–20
4. Pöldinger W (1987) Incidence and evaluation of risk of suicide in depression. In: Bizière K, Garratini S, Simon P (eds) Proceedings of Symposium ‘Quo vadis?’: diagnosis and treatment of depression, May 11–12, 1987, Montpellier, France
5. Versiani M et al. (1990) Tolerability of moclobemide, a new reversible inhibitor of monoamine oxidase-A, compared with other antidepressants and placebo. Acta Psychiatr Scand Suppl 82:29–34